The companies all use modified versions of the same lentiviral vectors used in ex vivo CAR-T therapy. “We're using the same basic vector backbone that's used to manufacture the cells ex vivo ...
Giulio Cossu, MD, speaks to the lingering safety concerns related to ex vivo gene therapy in Duchenne muscular dystrophy (DMD) as long-term data are yet to be established.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback